Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyCellularComponentSeh1-associated complex

SESN3 DEPDC5

1.50e-0416242GO:0035859
Pubmed

Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis.

SLC32A1 DEPDC5

4.56e-06524232113911
Pubmed

Identification of anchor genes during kidney development defines ontological relationships, molecular subcompartments and regulatory pathways.

TGFB1I1 SLC32A1 MAGI2 SYNM

9.71e-0619724421386911
Pubmed

The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1.

SESN3 DEPDC5

3.00e-051224225263562
Pubmed

Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.

MAGI2 DEPDC5 PHLDB1

4.74e-051022439734811
Pubmed

Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.

TGFB1I1 APOBR ARAP1 YLPM1

2.01e-0443024435044719
Pubmed

Three-dimensional visualization of testis cord morphogenesis, a novel tubulogenic mechanism in development.

TGFB1I1 VCAN ADAM19

3.27e-0419624319334288
Pubmed

A gene expression resource generated by genome-wide lacZ profiling in the mouse.

TGFB1I1 SESN3

4.24e-044424226398943
Pubmed

Human Antiviral Protein IFIX Suppresses Viral Gene Expression during Herpes Simplex Virus 1 (HSV-1) Infection and Is Counteracted by Virus-induced Proteasomal Degradation.

WDR33 VCAN MOV10

6.72e-0425124328077445
CoexpressionGSE9988_LOW_LPS_VS_VEHICLE_TREATED_MONOCYTE_DN

APOBR WDR33 DEPDC5 ZNF318

3.04e-05199244M5874
CoexpressionGSE7548_NAIVE_VS_DAY7_PCC_IMMUNIZATION_CD4_TCELL_UP

ZNF318 ESRRA ARAP1 MPG

3.10e-05200244M6836
CoexpressionGSE22025_UNTREATED_VS_TGFB1_AND_PROGESTERONE_TREATED_CD4_TCELL_UP

CHRD ESRRA VCAN ARAP1

3.10e-05200244M8383
ToppCellfacs-Lung-Endomucin_-18m-Myeloid-Neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC32A1 APOBR MOV10 ADAM19

1.59e-06161244e227f7b711475624cf80e77f235b1783d88d57b4
ToppCellfacs-Lung-Endomucin_-18m-Myeloid-neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC32A1 APOBR MOV10 ADAM19

1.59e-061612448280a029026c272cae9649b27575831b0dd4e242
ToppCellsaliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c2-CXCR4(low)|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)

APOBR CLCC1 ARAP1

7.12e-05151243b698ddc74565d47892c09c3f16d78038da2dd5e7
ToppCelldroplet-Liver-Hepatocytes-18m-Myeloid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LTO1 MAGI2 ARAP1

8.15e-05158243d3446fc98eff09c3626b47a2c90d07cd985378b5
ToppCelldroplet-Liver-Hepatocytes-18m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

LTO1 MAGI2 ARAP1

8.15e-05158243df614450e10629dc9115d7365397663e82f9e48f
ToppCelltumor_Lymph_Node_/_Brain-T/NK_cells-CD8+/CD4+_Mixed_Th|T/NK_cells / Location, Cell class and cell subclass

VCAN LMAN2L MPG

1.07e-0417324342c911ed16fabdabef063830e8407192d8bde950
ToppCellControl-B_cells-B_cells|Control / group, cell type (main and fine annotations)

SESN3 ZNF318 ADAM19

1.12e-04176243d2c353783bd78dc24f28e00d917b88d8294fb5df
ToppCellTCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-6|TCGA-Ovary / Sample_Type by Project: Shred V9

TGFB1I1 CHRD VCAN

1.16e-04178243142879e9393e721f9b05a6bb46995c9d6d713c95
ToppCellChildren_(3_yrs)-Mesenchymal-pericyte_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

SYNM PHLDB1 SHC2

1.22e-04181243451b87ac95154bb80018b8dd245b4a6389d81411
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SYNM ADAM19 SHC2

1.26e-04183243bc98df870de65aff6dab295c24cbc199c7f2aa15
ToppCellfacs-Skin-Skin_Anagen-18m-Mesenchymal-fibroblast|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

APOBR VCAN SHC2

1.28e-04184243fea4fe648e9749177d0783443dc26a7df5807883
ToppCellCOPD-Stromal-Pericyte|COPD / Disease state, Lineage and Cell class

TGFB1I1 CHRD PHLDB1

1.28e-04184243a56264a22dfc2d3672b20134ab7c3c7c23da5ae1
ToppCellfacs-Skin-Skin_Anagen-18m-Mesenchymal-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

APOBR VCAN SHC2

1.28e-0418424396a8a0a190bc293655fe7d80cbed8119c0da25f2
ToppCellfacs-Skin-Skin_Anagen-18m-Mesenchymal|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

APOBR VCAN SHC2

1.28e-04184243780eb72da43527f0c72effac3423ec7384f05f20
ToppCell21-Trachea-Mesenchymal-Airway_Smooth_Muscle|Trachea / Age, Tissue, Lineage and Cell class

TGFB1I1 CHRD PHLDB1

1.28e-0418424386a96cd88e50eacad1f0badfbbf6dc626f41725e
ToppCellPBMC-Mild-cDC_9|Mild / Compartment, Disease Groups and Clusters

TGFB1I1 KIAA1614 ADAM19

1.28e-041842432e0c9a2c40c892a2d435eafb31f1f838de9baf15
ToppCellFetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

PHLDB1 VCAN ADAM19

1.30e-04185243e58a009aaf342be019a909747b1895d5987d4daf
ToppCellCOPD-Stromal-Pericyte|World / Disease state, Lineage and Cell class

TGFB1I1 CHRD PHLDB1

1.32e-041862438adfd2d1fda4e8aecc95192ea627bf7ed5214b8d
ToppCellNasal_Brush-Immune-Neutrophils|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X

LTO1 CLCC1 VCAN

1.32e-04186243f5aa91dbef29f7efa2b9a728c6539d7541340cd4
ToppCell5'-Adult-Distal_Rectal-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TGFB1I1 PHLDB1 VCAN

1.32e-04186243f07e0c0d9c80ac9d8d679950e7d0c812becb85a3
ToppCellfacs-Skin-Anagen-24m-Mesenchymal|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CHRD SYNM VCAN

1.34e-04187243908df5520142d65fe32a003d26be14965082a1ea
ToppCellfacs-Skin-Anagen-24m-Mesenchymal-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CHRD SYNM VCAN

1.34e-04187243c1dfab0b0d7f519b9f13f4e0365ab41c4b2ae1ec
ToppCellfacs-Skin-Anagen-24m-Mesenchymal-fibroblast|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CHRD SYNM VCAN

1.34e-04187243b486cc5ac678051fea9d4c7db53b26a5a8427e60
ToppCellPCW_10-12-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung

TGFB1I1 PHLDB1 ADAM19

1.34e-04187243387cb27c8a20031cd87381a9e1172f1f62e1488b
ToppCellFetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

TGFB1I1 PHLDB1 ADAM19

1.36e-041882434d1e5f85342ae550086609d7680e32730b78b5d2
ToppCellE12.5-Mesenchymal|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

TGFB1I1 VCAN ARAP1

1.36e-041882439778dadc2bd7ded3a723e717d1c8cd3160e99c6c
ToppCellChildren_(3_yrs)-Mesenchymal-pericyte_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor

CHRD SYNM PHLDB1

1.36e-04188243ee151792c7ac9afe820f1a281c6dab383799f358
ToppCellE16.5-samps-Mesenchymal|E16.5-samps / Age Group, Lineage, Cell class and subclass

TGFB1I1 VCAN ARAP1

1.36e-041882433f0f662be684e3a4c6652e636cc135a39a1d2790
ToppCellFetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

SYNM ADAM19 SHC2

1.38e-0418924355a1776a4ce049959b3f13a43744c7314bc1f00a
ToppCellPCW_13-14-Mesenchymal-Mesenchymal_myocytic-mes_immature_ASM2_(12)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

TGFB1I1 PHLDB1 ADAM19

1.38e-041892430abc7a4900cc9033bc1be69b770ccc54a6bf41b4
ToppCellMesenchymal-airway_smooth_muscle_cell|World / Lineage, Cell type, age group and donor

TGFB1I1 PHLDB1 ADAM19

1.41e-04190243645e56b02edc3702c7db917b8ecd5eed0decaf71
ToppCellPCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung

SESN3 MAGI2 VCAN

1.41e-041902437986586b7c82e91c71102cc8c4d7a689ae63ab4d
ToppCell367C-Lymphocytic-NK_cells-NK_cell_B1|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

CLCC1 ZNF318 LMAN2L

1.41e-041902432434b8ad2976eab7d9147012c28454ab29670709
ToppCell367C-Lymphocytic-NK_cells-NK_cell_B1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

CLCC1 ZNF318 LMAN2L

1.43e-0419124339ef8e1d7cc3ebb11717e8a55501515e3b72b177
ToppCellTCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-3|TCGA-Ovary / Sample_Type by Project: Shred V9

TGFB1I1 VCAN ADAM19

1.43e-0419124380d30d8eedb4c70b58440646325bc04c5700803e
ToppCell3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.43e-04191243716dfa7fccbd62b5f574792e68a26dc6c45511dc
ToppCell3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.43e-041912431626b23a57429f835fddc052e3c57f63a4e5b8bb
ToppCell3'-Child09-12-SmallIntestine-Mesenchymal-Pericytes|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TGFB1I1 CHRD SYNM

1.45e-041922437aadc7c5bd03274f9861dde2febda5c37f8afc9c
ToppCellE15.5-Mesenchymal|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

TGFB1I1 VCAN ARAP1

1.47e-0419324322a9f5b61f197757f72840b9cb849cdb20430e72
ToppCell3'-Distal_airway-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.47e-0419324341ea268e7697101fe70d8ef1045f3a43b9311739
ToppCell3'-Distal_airway-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.47e-04193243b2abe939027a69b60d83a28d4d4cc53ba1dee4c5
ToppCellLeuk-UTI-Myeloid-CD14_Mono|Leuk-UTI / Disease, Lineage and Cell Type

APOBR ESRRA VCAN

1.47e-04193243d1eac8627d00629ed2e81d3b86778007304efcb7
ToppCell3'-Distal_airway-Mesenchymal-Mesenchymal_Myocytic|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.47e-0419324387ce81ff5b27d9c4300826d76ff5a62e9c408d5d
ToppCell3'-Distal_airway-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.47e-04193243d75f334fe3d9f39ef02a5de0f8202f7a761a8fc8
ToppCellE15.5-Mesenchymal-mesenchymal_fibroblast|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

TGFB1I1 VCAN ARAP1

1.47e-04193243b637e1c47a98009e7d19a6daac78f888fd12748f
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-E|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

APOBR VCAN ADAM19

1.47e-04193243d9bb77214bb92e8392cf74e3bfdf177a96fd71ea
ToppCell5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.49e-041942438f19e553f18c313c2a2ff9453884b9484b255d71
ToppCell3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.49e-041942433cffb5c58f6d5bd254f39ee9c41b7e1e4da0ff75
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.49e-041942435099e6ad7c19e5f8b73449d904aaefd97f1b1959
ToppCellE15.5-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

TGFB1I1 VCAN ARAP1

1.49e-04194243f2f7b9aad7588c8020a4850ff9333e1db8eafac7
ToppCell3'-Distal_airway-Mesenchymal|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.49e-04194243f5e3e675187afb6efa774f2a8d685efcf813de82
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.49e-0419424371734ef7b34ab33b349595368176fa0e1175d4d0
ToppCell5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.49e-0419424367fbb81b7d20cb63be27b2a2beea5b5689f8e08c
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.52e-04195243e10b21e4dba4483efc4c82d6e395524246ca14a8
ToppCellcellseq-Mesenchymal-Myocytic-Myocytic_1|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

TGFB1I1 CHRD SYNM

1.54e-04196243c373465e34e2dd581247962d59e0477aae877079
ToppCell3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.54e-041962439d18381d7aaa063094a5df769a04c73350471525
ToppCell5'-Airway_Nasal-Immune_Myeloid-Dendritic|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

SLC32A1 APOBR ADAM19

1.54e-04196243787088ce800d7148bad7265a971797da597b029a
ToppCell5'-Airway_Nasal-Immune_Myeloid|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

SLC32A1 APOBR ADAM19

1.54e-041962439c942bf9fc78caa173d2c7de5fe4c17f076c623b
ToppCellE17.5-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

TGFB1I1 VCAN ARAP1

1.54e-04196243028a06ed92f1c058dcbeacd335625bf529e87a7b
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

APOBR VCAN ADAM19

1.54e-04196243a44a648bf209ce037bfc7b3adfcb220aab60728c
ToppCellE18.5-Mesenchymal-Mesenchymal_structural|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

TGFB1I1 VCAN ARAP1

1.54e-0419624397e26622d9582b092c18ff5b7e957818f99d9631
ToppCellcellseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

TGFB1I1 CHRD SYNM

1.54e-041962438b5337ccf74de90e8b89a02ac00671af1de2cfff
ToppCell3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.54e-04196243a52cb512c6173be92aa9c4d96e2abbc32f45478d
ToppCell3'-Broncho-tracheal-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.54e-04196243afddacc0fb8b9c73dad5333137deb471a6ebdc06
ToppCellE18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

TGFB1I1 VCAN ARAP1

1.54e-04196243f429f045ba45e24717963315832150b12a115bfa
ToppCellkidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.56e-04197243d14e1f2ba94240c61eac435db43508a224d606a8
ToppCell3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TGFB1I1 CHRD SYNM

1.56e-0419724301249bd485a3734de87ae6ed9c749597f39c6335
ToppCell5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-myocytic-SMC_(PLPP2+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TGFB1I1 SYNM ADAM19

1.56e-04197243f4f686d20821af3e6f859b96edc31827a430e3de
ToppCellParenchymal-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_systemic_arterial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

TGFB1I1 CHRD SYNM

1.56e-041972433f078be0b0f5e16edfb6d517beb20ac6178767f0
ToppCellParenchymal-NucSeq-Endothelial-Endothelia_lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

SYNM ADAM19 SHC2

1.59e-041982439ab0db78394e730f6866b2db80047149024ad5f6
ToppCelldroplet-Bladder-BLADDER-1m-Epithelial-bladder_cell|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TGFB1I1 VCAN ARAP1

1.59e-041982438f202ed4692ea2c139ff05d4805c704ee4be095c
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.59e-04198243daf367b699726286f0f0f7b4f3a6cf70c462fbeb
ToppCellParenchymal-NucSeq-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

SYNM ADAM19 SHC2

1.59e-04198243e47d0e2c6353315c85d7007742bb16b0f05795ed
ToppCellkidney_cells-Hypertensive_with+without-CKD-Mesenchymal|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TGFB1I1 CHRD SYNM

1.59e-0419824354c8aa47040bc4977eed382514fc4ceae03f54f8
ToppCellcellseq-Mesenchymal-Myocytic|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

TGFB1I1 CHRD SYNM

1.61e-0419924320e62a7029fa0d214244cdf2a481fc5d78290438
ToppCell(02)_MMP9/10+|World / shred by cell type by condition

PHLDB1 VCAN ADAM19

1.61e-041992433f78eddeaa67d3b767aa38de765632166b09a4f0
ToppCellParenchyma_COVID-19-Stromal-TX-Smooth_muscle-2|Parenchyma_COVID-19 / Sample group, Lineage and Cell type

TGFB1I1 CHRD SYNM

1.61e-04199243c8bc05dece8b8a87d4a7a3e8112b924e15217de1
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

APOBR VCAN ADAM19

1.61e-04199243379bbd9cecf466b902411c54d74bd9885285b1ba
ToppCelldistal-mesenchymal-Pericyte-1|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.61e-04199243e72ac7a00405cde06293d7adac7dc40eb0cf87ba
ToppCellE16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

TGFB1I1 VCAN ARAP1

1.61e-041992439e87b64e16d595701c3beb07aa835afe3330bd10
ToppCellParenchymal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

TGFB1I1 SYNM ADAM19

1.61e-04199243b1753474152b82a0b811b9878c890a359e14919a
ToppCellE16.5-Mesenchymal-Mesenchymal_structural|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

TGFB1I1 VCAN ARAP1

1.61e-041992432cec0e370ee9bb3c88a7acb5519e9ea8ddb399bc
ToppCellLung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Smooth_muscle-2-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TGFB1I1 CHRD SYNM

1.61e-0419924378b245d40c1e169ff2d26907b63d732e34529c5f
ToppCellLung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Smooth_muscle-2|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)

TGFB1I1 CHRD SYNM

1.61e-041992438e1e95c3a4b856415af208be6ad977e575bac189
ToppCellmedial-mesenchymal-Pericyte-2|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243bbda454260016be92b539e220ecf7bcbbc6139e4
ToppCellBrain_organoid-organoid_Tanaka_cellReport-5w-Mesenchymal-Mesoderm|5w / Sample Type, Dataset, Time_group, and Cell type.

CHRD MAGI2 SHC2

1.63e-042002430927061536a664b4f7feb9e5b0a8c11ca0d5955c
ToppCellLung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Smooth_muscle-1-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TGFB1I1 CHRD SYNM

1.63e-0420024343b76e382b38b9856c07557a75e5b1ce0cee1d9e
ToppCellSepsis-Leuk-UTI-Myeloid-CD14+_Monocyte|Leuk-UTI / Disease, condition lineage and cell class

APOBR ESRRA VCAN

1.63e-0420024304d0164b80d424a308ada3fea6bb4a9d6cf686e3
ToppCellmild-HLA-DR+_CD83+_Monocyte|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

APOBR VCAN ARAP1

1.63e-04200243934c2efc780318c66d667ca75be0de350361d351
ToppCelldistal-mesenchymal-Pericyte-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243867935701fac71a3fe01578362da0676f959736c
ToppCellproximal-3-mesenchymal-Airway_Smooth_Muscle|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243e9a008bfe336002218c63d1c2231986e1b237621
ToppCellmedial-mesenchymal-Pericyte|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243f36d7cb6345daccebf76997f998e35d959b59452
ToppCellproximal-mesenchymal-Airway_Smooth_Muscle|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-042002435eeb8eb3fe74f5a8055c52ec77e38237bb63ed90
ToppCellParenchymal-10x5prime-Stromal-Peri/Epineurial_-NAF_epineurial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

CHRD SYNM KIAA1614

1.63e-0420024336de49593cf6ff1c9229fcceb150c1d68658a360
ToppCellParenchymal-10x5prime-Stromal-Pericyte-Muscle_pericyte_pulmonary|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

TGFB1I1 CHRD SYNM

1.63e-04200243f9bc22ff17bb1c751e6b05bca3f403836f33459a
ToppCelldistal-2-mesenchymal|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-0420024365a50f03b0027ccefb51b8f77afa283d4a3b3567
ToppCelldistal-mesenchymal-Pericyte|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243fe31287cfb51d45643bdedbaa5efc03ed87263c6
ToppCelldistal-1-mesenchymal-Pericyte|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-04200243ff205afda57b9267016f0c937445da1b0266af9b
ToppCellBiopsy_Other_PF-Mesenchymal-Smooth_Muscle_cells|Biopsy_Other_PF / Sample group, Lineage and Cell type

TGFB1I1 CHRD SYNM

1.63e-0420024355ac281901309e30978da1f7489386e54489721e
ToppCellproximal-mesenchymal-Airway_Smooth_Muscle-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

TGFB1I1 CHRD SYNM

1.63e-042002436fa339666c4032b29ac521e88f0e917a57013cde
DrugNapelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A

PHLDB1 ESRRA VCAN ARAP1 SHC2

1.67e-061962456824_UP
DrugNadolol [42200-33-9]; Up 200; 13uM; PC3; HT_HG-U133A

PHLDB1 ESRRA ARAP1 ADAM19

4.75e-051942444021_UP
DrugHecogenin [467-55-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A

SYNM ZNF318 ESRRA YLPM1

4.95e-051962447175_DN
DrugHydrochlorothiazide [58-93-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 ESRRA YLPM1

4.95e-051962441487_DN
DrugMoricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; MCF7; HT_HG-U133A

TGFB1I1 MAGI2 WDR33 ZNF318

4.95e-051962446000_UP
DrugJosamycin [16846-24-5]; Down 200; 4.8uM; MCF7; HT_HG-U133A

TGFB1I1 WDR33 ARAP1 ADAM19

5.04e-051972445692_DN
DrugAlfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 VCAN ARAP1

5.04e-051972446514_UP
DrugCefepime hydrochloride [123171-59-5]; Down 200; 7.4uM; MCF7; HT_HG-U133A

ESRRA ARAP1 ADAM19 YLPM1

5.14e-051982443581_DN
DrugGBR 12909 dihydrochloride [67469-78-7]; Down 200; 7.6uM; HL60; HG-U133A

APOBR ZNF318 ARAP1 YLPM1

5.14e-051982441625_DN
DrugPalmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 VCAN ARAP1

5.25e-051992444957_UP
Drugphosphonoacetaldehyde

SYNM ESRRA VCAN

2.18e-04112243CID000000490
DrugN-[4,5,7-Tricarboxyheptanoyl]-L-Gamma-Glutamyl-N-{2-[4-({5-[(Formylamino)methyl]-3-Furyl}methoxy)phenyl]ethyl}-D-Glutamine

CHRD ESRRA

2.43e-0422242CID011840961
Drugidoxifene

SYNM ESRRA

3.68e-0427242CID003034011
DrugPG-S

CHRD VCAN

4.55e-0430242CID000446796
Drugadenosine, 2'-deoxy

SYNM VCAN

5.51e-0433242CID000100053
Drugtriphenyltin fluoride

CHRD ESRRA

6.20e-0435242CID000009786
Drug4-methylumbelliferyl glucuronide

VCAN MPG

7.31e-0438242CID000091553
DrugTrichostatin A, Streptomyces sp.; Down 200; 1uM; HL60; HT_HG-U133A

APOBR VCAN ARAP1

8.43e-041782436193_DN
DrugSecurinine [5610-40-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 YLPM1

1.00e-031892436831_DN
Drug17-DMAG; Up 200; 0.1uM; MCF7; HT_HG-U133A

SYNM ARAP1 YLPM1

1.03e-031912436933_UP
DrugAntimycin A [1397-94-0]; Down 200; 7.2uM; MCF7; HT_HG-U133A

ESRRA ARAP1 LMAN2L

1.03e-031912432261_DN
DrugChlorpheniramine maleate [113-92-8]; Down 200; 10.2uM; PC3; HT_HG-U133A

ZNF318 VCAN YLPM1

1.03e-031912432055_DN
DrugDoxorubicin hydrochloride [25316-40-9]; Up 200; 6.8uM; MCF7; HT_HG-U133A

PHLDB1 VCAN ADAM19

1.03e-031912433291_UP
DrugAlbendazole [54965-21-8]; Down 200; 15uM; MCF7; HT_HG-U133A

SYNM ZNF318 ARAP1

1.05e-031922433164_DN
Drugvinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A

CLCC1 PHLDB1 YLPM1

1.05e-031922437556_UP
DrugAmbroxol hydrochloride [23828-92-4]; Down 200; 9.6uM; HL60; HG-U133A

CLCC1 ARAP1 LMAN2L

1.05e-031922431623_DN
DrugDelcorine; Up 200; 8.4uM; PC3; HT_HG-U133A

MAGI2 DEPDC5 VCAN

1.05e-031922433715_UP
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A

TGFB1I1 ADAM19 YLPM1

1.05e-031922436958_UP
DrugFluticasone propionate [80474-14-2]; Up 200; 8uM; MCF7; HT_HG-U133A

DEPDC5 ESRRA ARAP1

1.05e-031922434129_UP
DrugPhenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; PC3; HT_HG-U133A

PHLDB1 ESRRA VCAN

1.06e-031932435758_DN
Drug2gzl

SYNM VCAN

1.07e-0346242CID006102719
DrugCyclosporin A [59865-13-3]; Down 200; 3.4uM; MCF7; HT_HG-U133A

SYNM PHLDB1 ARAP1

1.08e-031942434411_DN
Drugphentolamine; Up 200; 11.5uM; MCF7; HT_HG-U133A_EA

SYNM ZNF318 ESRRA

1.08e-031942431138_UP
DrugErythromycin [114-07-8]; Down 200; 5.4uM; PC3; HT_HG-U133A

ESRRA VCAN ARAP1

1.08e-031942436729_DN
DrugSkimmianine [83-95-4]; Down 200; 15.4uM; MCF7; HT_HG-U133A

TGFB1I1 ZNF318 ARAP1

1.08e-031942436066_DN
DrugST021200; Down 200; 10uM; PC3; HT_HG-U133A

WDR33 ZNF318 VCAN

1.10e-031952437493_DN
DrugKarakoline [39089-30-0]; Down 200; 10.6uM; MCF7; HT_HG-U133A

PHLDB1 ADAM19 YLPM1

1.10e-031952436059_DN
DrugN6-methyladenosine [1867-73-8]; Up 200; 14.2uM; HL60; HT_HG-U133A

SYNM DEPDC5 ARAP1

1.10e-031952431271_UP
DrugDiphenidol hydrochloride [3254-89-5]; Up 200; 11.6uM; MCF7; HT_HG-U133A

VCAN ADAM19 SHC2

1.10e-031952437406_UP
DrugChicago sky blue 6B [2610-05-1]; Up 200; 4uM; MCF7; HT_HG-U133A

WDR33 VCAN ARAP1

1.10e-031952434971_UP
DrugTicarcillin sodium [4697-14-7]; Down 200; 9.4uM; HL60; HT_HG-U133A

WDR33 DEPDC5 ARAP1

1.10e-031952436146_DN
DrugClenbuterol hydrochloride [21898-19-1]; Down 200; 12.8uM; MCF7; HT_HG-U133A

ZNF318 ESRRA YLPM1

1.10e-031952435631_DN
DrugST021200; Up 200; 10uM; PC3; HT_HG-U133A

CLCC1 PHLDB1 YLPM1

1.10e-031952437559_UP
DrugCoralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; HL60; HT_HG-U133A

DEPDC5 ESRRA LMAN2L

1.10e-031952431298_UP
DrugOxamniquine [21738-42-1]; Up 200; 14.4uM; MCF7; HT_HG-U133A

ZNF318 VCAN ARAP1

1.10e-031952434124_UP
DrugFurazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A

WDR33 ARAP1 YLPM1

1.10e-031952433358_DN
DrugFlutamide [13311-84-7]; Up 200; 14.4uM; MCF7; HT_HG-U133A

CHRD VCAN ADAM19

1.11e-031962434361_UP
Drugrosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

ZNF318 ARAP1 YLPM1

1.11e-031962436950_UP
DrugPregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A

WDR33 ESRRA ARAP1

1.11e-031962432856_DN
DrugTolbutamide [64-77-7]; Down 200; 14.8uM; PC3; HT_HG-U133A

WDR33 PHLDB1 ESRRA

1.11e-031962434540_DN
DrugSR-95639A [115767-94-7]; Down 200; 10uM; MCF7; HT_HG-U133A

ZNF318 ESRRA ARAP1

1.11e-031962433272_DN
DrugGossypol [303-45-7]; Down 200; 7.8uM; MCF7; HT_HG-U133A

DEPDC5 ESRRA ARAP1

1.11e-031962433637_DN
DrugFamprofazone [22881-35-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

TGFB1I1 WDR33 ADAM19

1.11e-031962436029_DN
DrugBetamethasone [378-44-9]; Down 200; 10.2uM; PC3; HT_HG-U133A

ESRRA VCAN ARAP1

1.11e-031962436728_DN
DrugLevonordefrin [829-74-3]; Up 200; 21.8uM; MCF7; HT_HG-U133A

PHLDB1 YLPM1 SHC2

1.11e-031962437208_UP
DrugSyrosingopine [84-36-6]; Down 200; 6uM; PC3; HT_HG-U133A

SYNM ARAP1 YLPM1

1.11e-031962435733_DN
Drug(-)-Adenosine 3',5'-cyclic monophosphate [60-92-4]; Up 200; 12.2uM; HL60; HT_HG-U133A

ESRRA VCAN ARAP1

1.11e-031962432969_UP
DrugCephalexin monohydrate [23325-78-2]; Down 200; 11uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 ESRRA

1.11e-031962432628_DN
DrugICI182,780; Down 200; 1uM; PC3; HT_HG-U133A

DEPDC5 ZNF318 SHC2

1.11e-031962437495_DN
DrugPralidoxime chloride [51-15-0]; Down 200; 23.2uM; HL60; HT_HG-U133A

WDR33 ESRRA VCAN

1.11e-031962433066_DN
DrugBetonicine [515-25-3]; Down 200; 25.2uM; HL60; HT_HG-U133A

APOBR SYNM DEPDC5

1.11e-031962432207_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A

TGFB1I1 ZNF318 ESRRA

1.11e-031962435240_DN
DrugAC1Q6RZL

VCAN MPG

1.12e-0347242CID000001144
DrugZaprinast [37762-06-4]; Up 200; 14.8uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 ARAP1

1.13e-031972435349_UP
DrugCiprofibrate [52214-84-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A

ZNF318 ESRRA YLPM1

1.13e-031972433561_DN
DrugMethoxamine hydrochloride [61-16-5]; Down 200; 16.2uM; MCF7; HT_HG-U133A

WDR33 ESRRA ARAP1

1.13e-031972432848_DN
DrugAcetaminophen [103-90-2]; Up 200; 26.4uM; PC3; HT_HG-U133A

ESRRA VCAN ARAP1

1.13e-031972436284_UP
Drug1-phenylbiguanide hydrochloride; Up 200; 10uM; MCF7; HG-U133A

ZNF318 ARAP1 YLPM1

1.13e-0319724322_UP
DrugBezafibrate [41859-67-0]; Up 200; 11uM; HL60; HT_HG-U133A

WDR33 ESRRA VCAN

1.13e-031972431275_UP
Drug3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A

MAGI2 PHLDB1 VCAN

1.13e-031972436060_DN
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A

ZNF318 ADAM19 YLPM1

1.13e-031972436940_UP
DrugBetahistine mesylate [54856-23-4]; Down 200; 17.2uM; PC3; HT_HG-U133A

ESRRA ARAP1 YLPM1

1.13e-031972436611_DN
DrugMetrizamide [31112-62-6]; Up 200; 5uM; MCF7; HT_HG-U133A

PHLDB1 VCAN ADAM19

1.13e-031972434156_UP
DrugMeprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; MCF7; HT_HG-U133A

PHLDB1 ZNF318 SHC2

1.13e-031972436204_UP
DrugICI 182,780; Up 200; 1uM; MCF7; HG-U133A

TGFB1I1 LMAN2L YLPM1

1.13e-03197243367_UP
DrugRiluzole hydrochloride; Up 200; 14.8uM; HL60; HT_HG-U133A

WDR33 ZNF318 ARAP1

1.13e-031972432334_UP
Drugrofecoxib; Down 200; 10uM; HL60; HG-U133A

ZNF318 ARAP1 LMAN2L

1.13e-03197243371_DN
Diseaseplatelet crit

CHRD APOBR KIAA1614 ZNF318 MOV10 YLPM1

9.08e-05952246EFO_0007985
Diseasehearing loss

PHLDB1 ZNF318

1.36e-0367242EFO_0004238
Diseasecortical thickness

KIAA1614 PHLDB1 ZNF318 VCAN YLPM1

1.77e-031113245EFO_0004840
Diseaseunipolar depression

LTO1 MAGI2 CLCC1 VCAN YLPM1

2.51e-031206245EFO_0003761
Diseasemean fractional anisotropy measurement

KIAA1614 VCAN

2.70e-0395242EFO_0008399
DiseaseAdenoid Cystic Carcinoma

MAGI2 VCAN

2.99e-03100242C0010606
Diseasegastroesophageal reflux disease

VCAN YLPM1

3.05e-03101242EFO_0003948
Diseasebrain connectivity measurement

KIAA1614 VCAN MOV10

4.05e-03400243EFO_0005210
Diseasecomparative body size at age 10, self-reported

LTO1 MAGI2 MOV10

4.64e-03420243EFO_0009819
Diseasesystolic blood pressure, alcohol drinking

ZNF318 MOV10

4.84e-03128242EFO_0004329, EFO_0006335
DiseaseTinnitus

CHRD ZNF318

4.99e-03130242HP_0000360
Diseaseblood urea nitrogen measurement

KIAA1614 PHLDB1 ZNF318

5.69e-03452243EFO_0004741
DiseaseDiuretic use measurement

ZNF318 MOV10

8.29e-03169242EFO_0009928

Protein segments in the cluster

PeptideGeneStartEntry
GHYGFTLGEEDDEDR

VCAN

546

P13611
RGTHVYRGPEEEGDM

ADAM19

606

Q9H013
EGEAHCDIYGDRPRA

DEPDC5

961

O75140
DGRLHPGDELVYVDG

MAGI2

816

Q86UL8
EPYGGAVHEGRVERG

KIAA1614

891

Q5VZ46
YDHERDGRPTELGGC

LMAN2L

186

Q9H0V9
HEREEERGDGGFSVF

DNAJB14

236

Q8TBM8
AYLGPEDEAAHSRGG

MPG

126

P29372
ERFHGEGYREGYEEG

LTO1

16

Q8WV07
HEALLEYEAGRAGPG

ESRRA

356

P11474
DEHPGGHDRDDGSVY

SYNM

836

O15061
HSHDYLPQEREGEGG

MOV10

976

Q9HCE1
EEEDDHAYEGVPNGG

ARAP1

281

Q96P48
QREDSEGRCGDYHPE

APOBR

896

Q0VD83
EGRCGDYHPEGEAPR

APOBR

901

Q0VD83
DPEHRSYSDRGEPGA

CHRD

146

Q9H2X0
RQEEIDYRPDGGAGD

CLCC1

381

Q96S66
DGYVQADARGPPDHE

SHC2

396

P98077
PGFGYEDFARRGEEH

SESN3

331

P58005
PAGRERGEEGEHAYD

PHLDB1

1096

Q86UU1
GEERGHEEFPLDGRN

YLPM1

1196

P49750
GDEGFHEREGRPYCR

TGFB1I1

321

O43294
GDEGAEAPVEGDIHY

SLC32A1

71

Q9H598
PDHREFSEGDGRGAA

WDR33

1056

Q9C0J8
ADYARDGRGDHPGDS

ZNF318

116

Q5VUA4